A potential deal for Amgen (NASDAQ:AMGN) to buy Alexion Pharmaceuticals (NASDAQ:ALXN) “would be highly accretive,” Mizuho says.
Previously, a report suggested a $200/share deal could be in the making.
“We can debate the validity of the source, sure, but the concept of this happening doesn’t sound too crazy to me,” Mizuho analyst Salim Syed writes.
ALXN +1.8% to $116.94.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.